株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
企業レポート

PharmaLeaders:インドの医薬品メーカー大手10社の比較分析:主要企業の競争力分析

PharmaLeaders: Top 10 Pharmaceutical Companies in India Benchmark Report - Competitive Analysis of the Leading Players in 2013

発行 GlobalData 商品コード 278784
出版日 ページ情報 英文 162 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
PharmaLeaders:インドの医薬品メーカー大手10社の比較分析:主要企業の競争力分析 PharmaLeaders: Top 10 Pharmaceutical Companies in India Benchmark Report - Competitive Analysis of the Leading Players in 2013
出版日: 2013年07月31日 ページ情報: 英文 162 Pages
概要

当レポートでは、インドの製薬産業における上位企業10社の財政・経営状況について分析し、様々な観点・指標から各社の財政状況や経営効率・実績、事業展開状況などを比較分析すると共に、主要企業のSWOT分析や、今後の市場の方向性、解決すべき課題などについて調査・考察して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 インドの医薬品産業の動向

  • 概要
  • インドにおける知的所有権
  • 製薬企業が成長するのに最適な、高水準の製造施設
  • 企業間競争による能力開発の実現
  • 政府の政策・取り組みによる需要促進
  • インドの製薬企業によるANDA(略式新薬承認申請)申請数の増加
  • インドの製薬企業に対するGDUFA法のコスト効果
  • 萌芽し始めたバイオシミラー市場
    • 準規制市場から規制市場への段階的転換
    • インドで上市されたバイオシミラー

第4章 企業分析(事業概要、SWOT分析)

  • Sun Pharmaceuticals:比較基準となる代表的企業
  • Wockhardt
  • Cipla
  • Ranbaxy
  • Lupin Pharmaceuticals
  • Zydus Cadila
  • Glenmark
  • Torrent Pharmaceuticals
  • Dr. Reddy's
  • Aurobindo Pharmaceuticals

第5章 GlobalDataによる比較分析

  • Sun Pharmaceuticals:インドの製薬産業の代表的企業

第6章 財務管理

  • 競争の枠組み
  • 概要
  • 財務管理:ヒートマップ(比較表)
  • 財務指標
    • 市場収益:上位・下位企業
    • 市場収益率:上位・下位企業
    • 営業収益額:上位・下位企業
    • 営業収益の年間成長率:上位・下位企業
    • 営業利益率:上位・下位企業

第7章 支出管理

  • 競争の枠組み
  • 概要
  • 支出管理:ヒートマップ(比較表)
  • 支出指標
    • 一般管理販売費:上位・下位企業
    • 一般販売管理費の対市場収益比率:上位・下位企業
    • 一般管理販売費の年間増加率:上位・下位企業
    • 営業支出:上位・下位企業

第8章 資本管理

  • 競争の枠組み
  • 概要
  • 資本管理:ヒートマップ(比較表)
  • 資本管理指標
    • 負債比率:上位・下位企業
    • 現金比率:上位・下位企業
    • 当座比率:上位・下位企業
    • 投資収益率(ROI):上位・下位企業

第9章 資源管理

  • 競争の枠組み
  • 概要
  • 資源管理:ヒートマップ(比較表)
  • 財務指標
    • 従業員1人当たり市場収益:上位・下位企業
    • 従業員1人当たり支出額:上位・下位企業

第10章 地域別の市場動向

  • インド
  • 欧州・中東・アフリカ(EMEA)地域
  • 北米
  • 他の国々

第11章 今後の戦略の見通し

  • インドの医薬品産業の現在の成長状況は、今後も継続する見通し
  • 研究開発(R&D)に対する関心の増大
  • 政府の薬価改訂に伴う、利益率の更なる低下
  • 外資系企業との激しい競争が、国内の小規模企業の発展を阻害する
  • 特許法による圧力増大が、国内系企業への課題となる

第12章 付録

図表一覧

目次
Product Code: GDHC003PLR

Abstract

Summary

GlobalData's "PharmaLeaders: Top 10 Pharmaceutical Companies in India Benchmark Report - Competitive Analysis of the Leading Players in 2013" applies GlobalData's proprietary ranking methodology to compare the competitive position of 10 India-based pharmaceutical companies on 15 financial metrics. The performance of each of these companies is analyzed based on their financial performance, cost-containment, capital structure, and efficiency to illustrate the different strategies these companies are using to increase shareholder value and capture market share from branded pharmaceuticals manufacturers. In addition to the financial metrics, this report presents competitive landscapes of the various markets in which these companies operate, as well as detailed company profiles, including SWOT analyses, of these major players. It also describes the operations strategies of these companies.

Throughout the report, GlobalData's analysts provide you with expert insight, expanding on each strategy and factor discussed, with the aim of providing you with the tools you need to make informed business decisions.

Highlights

About the Report

This report is an essential source of information and analysis on the Indian pharmaceutical industry. Using detailed company data, financial analysis, corporate strategy, and market trends analysis, GlobalData has highlighted 10 companies in the Indian pharmaceuticals space, forming a basis for in-depth analysis of the current and future growth drivers of the domestic pharmaceuticals market. The report discusses the key factors shaping and driving the Indian pharmaceutical industry, and provides insight on the competitive landscape and emerging strategies that are expected to significantly alter the market position of the industry leaders.

Key Questions Answered

  • What are the drivers of the Indian pharmaceutical industry?
  • What is the forecast for the Indian pharmaceutical market to 2020?
  • What specific strategies are pharmaceutical companies in India employing to capture market share from branded and generic pharmaceutical companies worldwide?
  • How are these companies dealing with cost-containment to increase their margin?
  • How does my assets utilization and overall manufacturing efficiency match up with theirs?
  • How are these pharmaceutical companies maximizing their capital spending to attain a competitive advantage?

Scope

  • The report includes a financial model, which uses GlobalData's proprietary benchmarking methodology to rank 10 leading pharmaceutical companies in India on 15 different financial metrics
  • The report provides analysis of the key drivers and trends shaping the Indian pharmaceutical industry
  • The report provides a geographic segmentation and competitive assessment of the various markets in which the companies covered in the report market their products.
  • The report contains expert insights on the corporate strategies of Indian pharmaceutical companies seeking competitive advantage in the highly competitive generics industry
  • The report includes in-depth company profiles of the 10 Indian pharmaceutical companies featured, including insightful SWOT analyses

Key Benefits

  • Understand the key factors driving the substantial growth being witnessed in the Indian pharmaceutical industry and the market's outlook through 2020
  • Benchmark your company's performance against other pharmaceutical companies in India to identify strengths that can be leveraged and/or areas of possible improvement
  • Plan your entry and/or expansion activities involving the Indian pharmaceutical market by understanding the market dynamics and identifying possible partners and/or acquisition targets
  • Analyze and track the strategies that successful pharmaceutical companies in India are using to gain share in the increasingly competitive market
  • Understand the underlying financial metrics that differentiate certain companies from the pack in terms of growth and profitability, spending, asset structure, and efficiency
  • Use this information as an independent source for your due diligence and transaction strategy

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Report Scope
  • 2.2. Upcoming Related Reports
  • 2.3. Recently Published Reports
  • 2.4. GlobalData's Benchmarking Methodology

3. India's Pharmaceutical Industry Dynamics

  • 3.1. Overview
  • 3.2. Intellectual Property Rights in India
  • 3.3. Quality Manufacturing Facilities Create an Ideal Environment for Pharmaceuticals to Thrive
  • 3.4. Inter-Firm Competition Enables Capabilities Development
  • 3.5. Government Policies and Initiatives Drive Demand
  • 3.6. Increased ANDA Filings by Indian Drug Companies
  • 3.7. Cost Effect of GDUFA on Indian Drug Companies
  • 3.8. A Budding Biosimilars Market
    • 3.8.1. Gradual Transition from a Semi-Regulated to a Regulated Market
    • 3.8.2. Marketed Biosimilars in India

4. Company Analysis

  • 4.1. Sun Pharmaceuticals: The Benchmark Leader
    • 4.1.1. Business Overview
    • 4.1.2. SWOT Analysis
  • 4.2. Wockhardt
    • 4.2.1. Business Overview
    • 4.2.2. SWOT Analysis
  • 4.3. Cipla
    • 4.3.1. Business Overview
    • 4.3.2. SWOT Analysis
  • 4.4. Ranbaxy
    • 4.4.1. Business Overview
    • 4.4.2. SWOT Analysis
  • 4.5. Lupin Pharmaceuticals
    • 4.5.1. Business Overview
    • 4.5.2. SWOT Analysis
  • 4.6. Zydus Cadila
    • 4.6.1. Business Overview
    • 4.6.2. SWOT Analysis
  • 4.7. Glenmark
    • 4.7.1. Business Overview
    • 4.7.2. SWOT Analysis
  • 4.8. Torrent Pharmaceuticals
    • 4.8.1. Business Overview
    • 4.8.2. SWOT Analysis
  • 4.9. Dr. Reddy's
    • 4.9.1. Business Overview
    • 4.9.2. SWOT Analysis
  • 4.10. Aurobindo Pharmaceuticals
    • 4.10.1. Business Overview
    • 4.10.2. SWOT Analysis

5. GlobalData's Benchmark Rankings

  • 5.1. Sun Pharmaceuticals: India's Leading Pharmaceutical Company

6. Financial Management

  • 6.1. Competitive Framework
  • 6.2. Overview
  • 6.3. Financial Management: Heat Map
  • 6.4. Financial Metrics
    • 6.4.1. Revenue Leaders
    • 6.4.2. Revenue Laggards
    • 6.4.3. Revenue Growth Leaders
    • 6.4.4. Revenue Growth Laggards
    • 6.4.5. Operating Income Leaders
    • 6.4.6. Operating Income Laggards
    • 6.4.7. Operating Income YTY Growth Leaders
    • 6.4.8. Operating Income YTY Growth Laggards
    • 6.4.9. Operating Margin Leaders
    • 6.4.10. Operating Margin Laggards

7. Expense Management

  • 7.1. Competitive Framework
  • 7.2. Overview
  • 7.3. Expense Management: Heat Map
  • 7.4. Expense Metrics
    • 7.4.1. SG&A Spending Leaders
    • 7.4.2. SG&A Spending Laggards
    • 7.4.3. SG&A Expenditures as a Percentage of Revenue Leaders
    • 7.4.4. SG&A Expenditures as a Percentage of Revenue Laggards
    • 7.4.5. SG&A Spending YTY Change Leaders
    • 7.4.6. SG&A YTY Spending Change Laggards
    • 7.4.7. Operating Expenses as a Percentage of Revenue Leaders
    • 7.4.8. Operating Expenses Laggards

8. Capital Management

  • 8.1. Competitive Framework
  • 8.2. Overview
  • 8.3. Competitive Framework: Heat Map
  • 8.4. Capital Management Metrics
    • 8.4.1. Debt Ratio Leaders
    • 8.4.2. Debt Ratio Laggards
    • 8.4.3. Cash Ratio Leaders
    • 8.4.4. Cash Ratio Laggards
    • 8.4.5. Quick Ratio Leaders
    • 8.4.6. Quick Ratio Laggards
    • 8.4.7. ROI Leaders
    • 8.4.8. ROI Laggards

9. Resource Management

  • 9.1. Competitive Framework
  • 9.2. Overview
  • 9.3. Resource Management: Heat Map
  • 9.4. Financial Metrics
    • 9.4.1. Revenue per Employee Leaders
    • 9.4.2. Revenue per Employee Laggards
    • 9.4.3. Expenditure per Employee Leaders
    • 9.4.4. Expenditure per Employee Laggards

10. Geographical Segmentation

  • 10.1. India
  • 10.2. Europe, Middle East, and Africa
  • 10.3. North America
  • 10.4. Rest of World

11. Strategic Outlook

  • 11.1. Current Growth in the Indian Pharmaceutical Industry Expected to Continue
  • 11.2. Increased Focus on R&D
  • 11.3. Government's Pricing Revision Will Further Reduce Margins
  • 11.4. Stiff Competition from Multinationals May Stymie Development of Smaller Domestic Players
  • 11.5. Growing Pressures on Indian Patent Laws Could Challenge Domestic Companies

12. Appendix

  • 12.1. Bibliography
  • 12.2. Abbreviations
  • 12.3. Research Methodology
    • 12.3.1. Coverage
    • 12.3.2. Secondary Research
    • 12.3.3. Expert Panel Validation
  • 12.4. About the Authors
    • 12.4.1. Analyst
    • 12.4.2. Director of Healthcare Industry Dynamics
    • 12.4.3. Global Head of Healthcare Research and Consulting
  • 12.5. About the Industry Dynamics Team
  • 12.6. About GlobalData
  • 12.7. Disclosure Information
  • 12.8. Disclaimer

List of Tables

  • Table 1: First-Time Generic Drug Approvals, 2012 - Part 1
  • Table 2: First-Time Generic Drug Approvals, 2012 - Part 2
  • Table 3: First-Time Generic Drug Approvals, 2012 - Part 3
  • Table 4: First-Time Generic Drug Approvals, 2012 - Part 4
  • Table 5: Biosimilars Currently Marketed in India
  • Table 6: Wockhardt's Product Pipeline
  • Table 7: Lupin's Product Pipeline
  • Table 8: Glenmark: Novel Drugs Pipeline
  • Table 9: Torrent Pharmaceuticals' Current Discovery Portfolio
  • Table 10: Dr. Reddy's Currently Marketed Biosimilars
  • Table 11: GlobalData's Benchmark Rankings, Top 10 Pharmaceutical Companies in India, 2012
  • Table 12: Top 10 Indian Pharmaceutical Companies' FM Composite Scores and Overall FM Scores, 2012
  • Table 13: Revenue-Leading Companies' FM Composite Scores and Overall FM Scores, 2012
  • Table 14: Top Three Revenue Laggards in 2012
  • Table 15: Top Three Revenue Growth Leaders in 2012
  • Table 16: Top Three Revenue Growth Laggards in 2012
  • Table 17: Top Three Operating Income Leaders in 2012
  • Table 18: Top Three Operating Income Laggards in 2012
  • Table 19: Top Three YTY Operating Income Growth Leaders in 2012
  • Table 20: Top Three YTY Operating Income Growth Laggards in 2012
  • Table 21: Top Three Operating Margin Leaders in 2012
  • Table 22: Top Three Operating Margin Laggards in 2012
  • Table 23: Top 10 Indian Pharmaceutical Companies' Composite and Overall EM Scores, 2012
  • Table 24: Top SG&A Spending Leaders in 2012
  • Table 25: Top SG&A Spending Laggards in 2012
  • Table 26: Top SG&A Spending as a Percentage of Revenue Leaders, 2012
  • Table 27: Top SG&A Spending as a Percentage of Revenue Laggards, 2012
  • Table 28: Top SG&A Spending YTY Change Leaders
  • Table 29: Top SG&A Spending YTY Change Leaders
  • Table 30: Top Operating Expenses as a Percentage of Revenue Leaders
  • Table 31: Top Operating Expenses Laggards as a Percentage of Revenue
  • Table 32: Top 10 Indian Pharmaceutical Companies' Composite and Overall CM Scores, 2012
  • Table 33: Top Debt-to-Assets Leaders in 2012
  • Table 34: Debt-to-Assets Laggards in 2012
  • Table 35: Cash Ratio Leaders in 2012
  • Table 36: Cash Ratio Laggards in 2012
  • Table 37: Quick Ratio Leaders in 2012
  • Table 38: Quick Ratio Laggards in 2012
  • Table 39: ROI Leaders in 2012
  • Table 40: ROI Laggards in 2012
  • Table 41: Top 10 Indian Pharmaceutical Companies' Composite and Overall RM Scores, 2012
  • Table 42: Top Three Revenue per Employee Leaders in 2012
  • Table 43: Top Three Revenue per Employee Laggards in 2012
  • Table 44: Top Three Expenditure per Employee Leaders in 2012
  • Table 45: Top Three Expenditure per Revenue Laggards in 2012

List of Figures

  • Figure 1: Value of Pharmaceutical Exports from India, 2002-2012
  • Figure 2: Sun Pharmaceuticals: SWOT Analysis
  • Figure 3: Wockhardt: SWOT Analysis
  • Figure 4: Cipla: SWOT Analysis
  • Figure 5: Ranbaxy: SWOT Analysis
  • Figure 6: Lupin Pharmaceuticals: SWOT Analysis
  • Figure 7: Zydus Cadila: SWOT Analysis
  • Figure 8: Glenmark: SWOT Analysis
  • Figure 9: Torrent Pharma: SWOT Analysis
  • Figure 10: Dr. Reddy's: SWOT Analysis
  • Figure 11: Aurobindo Pharmaceuticals: SWOT Analysis
  • Figure 12: Competitive Assessment of the Top 10 Pharmaceutical Companies in India, 2012
  • Figure 13: Leading Pharmaceutical Companies in India by Revenue in 2011 and 2012
  • Figure 14: Leading Pharmaceutical Companies in India by YTY Revenue Growth in 2012
  • Figure 15: Leading Pharmaceutical Companies in India by Operating Income ($m), 2011 and 2012
  • Figure 16: Leading Pharmaceutical Companies in India by YTY Operating Income Growth
  • Figure 17: Leading Pharmaceutical Companies in India by Operating Margin in 2011 and 2012
  • Figure 18: Competitive Landscape of the Top 10 Pharmaceutical Companies in India in 2012 - SG&A Expenses as a Percentage of Revenue vs. Operating Expenses as a Percentage of Revenue
  • Figure 19: Leading Pharmaceutical Companies in India by SG&A Spending as a Percentage of Revenue, 2011 and 2012
  • Figure 20: Leading Pharmaceutical Companies in India by SG&A Spending, 2011 and 2012
  • Figure 21: Leading Pharmaceutical Companies in India by SG&A Spending as a Percentage of Revenue, 2012
  • Figure 22: Leading Pharmaceutical Companies in India by SG&A Expenditures YTY Change, 2012
  • Figure 23: Leading Pharmaceutical Companies in India by Operating Expenses as a Percentage of Revenue, 2011 and 2012
  • Figure 24: Competitive Landscape of the Top 10 Players in the Indian Pharmaceutical Industry - Debt Ratio vs. Cash Ratio, 2012
  • Figure 25: Leading Pharmaceutical Companies in India by Debt Ratio, 2011 and 2012
  • Figure 26: Leading Pharmaceutical Companies in India by Cash Ratio, 2011 and 2012
  • Figure 27: Leading Pharmaceutical Companies in India by Quick Ratio, 2011 and 2012
  • Figure 28: Leading Pharmaceutical Companies in India by ROI, 2011 and 2012
  • Figure 29: Global Headcount of the Top 10 Players in the Indian Pharmaceutical Industry
  • Figure 30: Competitive Landscape of the Top 10 Players in the Indian Pharmaceutical Industry
  • Figure 31: Leading Pharmaceutical Companies in India by Revenue per Employee, 2011 and 2012
  • Figure 32: Leading Pharmaceutical Companies in India by Expenditure per Employee, 2012
  • Figure 33: Forecast Growth in the Indian Pharmaceutical Market, 2013-2020 ($bn)
  • Figure 34: Competitive Landscape of the Top 10 Domestic Pharmaceutical Companies in India, 2012
  • Figure 35: Competitive Landscape of the Leading India-based Pharmaceutical Companies in the EMEA Region, 2012
  • Figure 36: Competitive Landscape of the Leading Indian Pharmaceutical Companies in North America, 2012
  • Figure 37: Competitive Landscape of the Leading Indian Pharmaceutical Companies in the ROW, 2012
  • Figure 38: Forecast Growth in the Indian Pharmaceutical Market, 2013-2020 ($bn)
Back to Top